Cardona, Andrés F. http://orcid.org/0000-0003-3525-4126
Jaramillo-Velásquez, Daniel
Ruiz-Patiño, Alejandro
Polo, Carolina
Jiménez, Enrique
Hakim, Fernando
Gómez, Diego
Ramón, Juan Fernando
Cifuentes, Hernando
Mejía, Juan Armando
Salguero, Fernando
Ordoñez, Camila
Muñoz, Álvaro
Bermúdez, Sonia
Useche, Nicolas
Pineda, Diego
Ricaurte, Luisa
Zatarain-Barrón, Zyanya Lucia
Rodríguez, July
Avila, Jenny
Rojas, Leonardo
Jaller, Elvira
Sotelo, Carolina
Garcia-Robledo, Juan Esteban
Santoyo, Nicolas
Rolfo, Christian
Rosell, Rafael
Arrieta, Oscar
Funding for this research was provided by:
foundation for clinical and applied cancer research/oncolgroup (014-2018)
Article History
Received: 8 July 2021
Accepted: 19 August 2021
First Online: 9 September 2021
Declarations
:
: Andrés F. Cardona discloses financial research support from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Foundation Medicine, Roche Diagnostics, Termo Fisher, Broad Institute, Amgen, Flatiron Health, Teva Pharma, Rochem Biocare, Bayer, INQBox and The Foundation for Clinical and Applied Cancer Research—FICMAC. Additionally, he was linked and received honoraria as an advisor, participate in speakers' bureau. He gave expert testimony to EISAI, Merck Serono, Jannsen Pharmaceutical, Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly, Guardant Health, Illumina, and Foundation for Clinical and Applied Cancer Research—FICMAC. Oscar Arrieta reports personal fees from Pfizer, grants and individual fees from Astra Zeneca, grants and individual fees from Boehringer-Ingelheim, Lilly, Merck, Bristol Myers Squibb, Roche, outside the submitted work. Christian Rolfo reports relation with Mylan, Archer Biosciences, Oncopass, Inivata, Merck Serono Novartis, MSD, Boehringer Ingelheim, Guardant Health, etc. AstraZeneca as part of Speakers' Bureau. Also, he received research funding from Pfizer and had uncompensated Relationships with OncoDNA, Biomark, and Guardant Health. Leonardo Rojas received honoraria as an advisor, participate in speakers’ bureau from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Astra Zeneca and Eli Lilly. Additionally, he was linked and received honoraria as researcher. All other authors have no conflicts to declare.
: This study was reviewed and approved by ONCOLGroup Platform—Registration No. 2018/21904, Cayre, Clínica del Country, Bogotá, Colombia. All included patients provided signed informed consent and accepted the tumor tissue analysis. An Institutional Review Board and Privacy Board waiver was obtained to facilitate retrospective collection of clinical, pathologic and molecular data.